Founder, Young Inventors
Strategic Advisor, Innovation and Strategy, Citigroup
President and CEO, Onyx Pharmaceuticals
Professor, J. David Gladstone Institute of Cardiovascular Disease
Professor, Biochemistry and Biophysics, UCSF
Principal Researcher, Microsoft Research Silicon Valley Laboratory
Co-Founder and CEO, Seattle Genetics
Vice President, Kauffman Foundation
|
Lexington, MA-based Cubist Pharmaceuticals announced it will pay $4.7 million, plus another $1 million in research and operating costs, for an exclusive option to buy Seattle’s Illumigen Biosciences. Illumigen’s lead compound is a protein-based treatment for hepatitis C. If Cubist exercises its option it will pay $9 million upfront, plus development and regulatory milestone payments that could surpass $330 million.
San Francisco · 6/7/12
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
